Download File

Image Modality: Illustration Table Figure

Description:

This research was designed to develop a general understanding from U.S. cardiologists of their perceptions of access to new therapies and usage for their patients with a focus specifically on angiotensin receptor-neprilysin inhibitor (ARNIs), Proprotein convertase subtilisin/kexin type 9 (PCSK9i) and Novel Oral Anticoagulants (NOACs). The survey was sent to 405 current, active fellows of the American College of Cardiology, and 151 panelists completed the survey for an overall response rate of 37%. The survey found that:

1. Implementing new therapies is a problem, requiring more professional time due to administrative barriers;
2. The top two barriers to trying new therapies are a) cost and b) prior authorization documentation;
3. Cardiologists feel very favorably about prescribing new medications;
4. Formulary restrictions create disparities in care and contribute to patient confusion;
5. ACC should take a leadership role in helping reduce the administrative burden;
6. Of the three new therapies evaluated (NOACs, ARNIs, PCSK9s), PCSK9s are most likely to receive delays or denials;
7. Cardiologists would be much more likely to prescribe appropriate new therapies if they did not experience delays/denials.

Date: November 30, 2016    

Authors:   Paul Theriot; Anne Rzeszut

Source: ACC Media File

Keywords: Anticoagulants, Heart Failure, Dyslipidemias